Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma
Ester Lozano, Tania Díaz, Mari-Pau Mena, et al.
The Journal of Immunology (2018) Vol. 200, Iss. 8, pp. 2581-2591
Open Access | Times Cited: 25

Showing 25 citing articles:

Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
Muthulekha Swamydas, Elena V. Murphy, James J. Ignatz-Hoover, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 81
Multiple Myeloma Therapy: Emerging Trends and Challenges
Danai Dima, Dongxu Jiang, Divya Jyoti Singh, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4082-4082
Open Access | Times Cited: 41
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
Tobias Zeller, Ira A. Münnich, Roland Windisch, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy
Helmi Alfarra, Jackson A. Weir, Stacy Grieve, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 46
Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
Heyu Chen, Yuanzhi Chen, Mi Deng, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000515-e000515
Open Access | Times Cited: 44
Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma
Ester Lozano, Mari-Pau Mena, Tania Díaz, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 17, pp. 4688-4698
Open Access | Times Cited: 43
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Mi Deng, Heyu Chen, Xiaoye Liu, et al.
Antibody Therapeutics (2021) Vol. 4, Iss. 1, pp. 16-33
Open Access | Times Cited: 33
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Miao Xian, Qiang Wang, Liuling Xiao, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma
Lin Fu, Zhiheng Cheng, Fen Dong, et al.
Journal of Cancer (2019) Vol. 11, Iss. 5, pp. 1182-1194
Open Access | Times Cited: 38
Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
Noémie Leblay, Ranjan Maity, Fajer Hasan, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 37
Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy
Calvin D. De Louche, Ali Roghanian
JCI Insight (2022) Vol. 7, Iss. 2
Open Access | Times Cited: 21
Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma
Jing Fan, Jiayan Li, Jianbo Han, et al.
Molecular Immunology (2021) Vol. 136, pp. 82-97
Closed Access | Times Cited: 18
MHC1/LILRB1 axis as an innate immune checkpoint for cancer therapy
Ziyi Hu, Qiaodong Zhang, Zehua He, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Cross‐platform immunophenotyping of human peripheral blood mononuclear cells with four high‐dimensional flow cytometry panels
Alexander T. Heubeck, Adam K. Savage, Katherine Henderson, et al.
Cytometry Part A (2022) Vol. 103, Iss. 6, pp. 500-517
Open Access | Times Cited: 8
Expression of leukocyte immunoglobulin-like receptor B2 in hepatocellular carcinoma and its clinical significance
Xinwen Li, Xiaojuan Wei, Huirong Xu, et al.
Journal of Cancer Research and Therapeutics (2018) Vol. 14, Iss. 7, pp. 1655-1655
Open Access | Times Cited: 14
Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma
Vishal Jindal, John Khoury, Ruby Gupta, et al.
American Journal of Clinical Oncology (2020) Vol. 43, Iss. 5, pp. 371-377
Closed Access | Times Cited: 10
Leukocyte immunoglobulin-like receptor subfamily B member 1 potentially acts as a diagnostic and prognostic target in certain subtypes of adenocarcinoma
Jianghong Cheng, Xingchun Gao, Xiaohua Zhang, et al.
Medical Hypotheses (2020) Vol. 144, pp. 109863-109863
Closed Access | Times Cited: 10
Why Immunotherapy Fails in Multiple Myeloma
Luis Gerardo Rodríguez‐Lobato, Aina Oliver‐Caldés, David F. Moreno, et al.
Hemato (2020) Vol. 2, Iss. 1, pp. 1-42
Open Access | Times Cited: 8
The LILRB family in hematologic malignancies: prognostic associations, mechanistic considerations, and therapeutic implications
Alan W. Hodges, Rachel Dubuque, Shu‐Hsia Chen, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access
The BLIMP1—EZH2 nexus in a non-Hodgkin lymphoma
Kimberley Jade Anderson, Árný Björg Ósvaldsdóttir, Birgit Atzinger, et al.
Oncogene (2020) Vol. 39, Iss. 28, pp. 5138-5151
Open Access | Times Cited: 3
A Comprehensive Targeted Panel of 282 Genes: Unveiling Key Biomarkers in Multiple Myeloma
Vivek Ruhela, Rupin Oberoi, Ritu Gupta, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
BDL-SP: A Bio-inspired DL model for the identification of altered Signaling Pathways in Multiple Myeloma using WES data.
Vivek Ruhela, Lingaraja Jena, Gurvinder Kaur, et al.
PubMed (2023) Vol. 13, Iss. 4, pp. 1155-1187
Closed Access
The BLIMP1 – EZH2 nexus in a non-Hodgkin lymphoma
Kimberley Jade Anderson, Árný Björg Ósvaldsdóttir, Birgit Atzinger, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2019)
Open Access
Future prospects of chimeric antigen receptor T‐cell therapy for multiple myeloma
Carlos Fernández de Larrea, Sham Mailankody, Ola Landgren, et al.
Advances in Cell and Gene Therapy (2019) Vol. 3, Iss. 1
Open Access
Potential Treatment for Multiple Myeloma: Immune Checkpoint Inhibitors
Jiaxin Wang, Jiaxiong Tan, Yuhong Lu
International Journal of Immunology (2021) Vol. 9, Iss. 3, pp. 59-59
Open Access
Page 1

Scroll to top